[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Gilead Sciences Inc (GILD)

Gilead Sciences Inc (GILD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 155,754,944
  • Shares Outstanding, K 1,241,570
  • Annual Sales, $ 29,443 M
  • Annual Income, $ 8,510 M
  • EBIT $ 10,370 M
  • EBITDA $ 13,130 M
  • 60-Month Beta 0.31
  • Price/Sales 5.37
  • Price/Cash Flow 12.15
  • Price/Book 6.74

Options Overview Details

View History
  • Implied Volatility 27.26% (+0.38%)
  • Historical Volatility 26.17%
  • IV Percentile 28%
  • IV Rank 30.92%
  • IV High 40.29% on 10/13/25
  • IV Low 21.43% on 12/10/25
  • Expected Move (DTE 8) 3.17 (2.56%)
  • Put/Call Vol Ratio 0.51
  • Today's Volume 5,380
  • Volume Avg (30-Day) 9,531
  • Put/Call OI Ratio 0.47
  • Today's Open Interest 194,734
  • Open Int (30-Day) 164,812
  • Expected Range 120.59 to 126.93

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 31 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-5.88
  • Number of Estimates 7
  • High Estimate $2.05
  • Low Estimate $-7.50
  • Prior Year $2.01
  • Growth Rate Est. (year over year) -392.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
121.39 +1.95%
on 06/10/26
137.20 -9.80%
on 05/29/26
-5.91 (-4.56%)
since 05/18/26
3-Month
121.39 +1.95%
on 06/10/26
142.97 -13.44%
on 04/09/26
-17.53 (-12.41%)
since 03/18/26
52-Week
104.46 +18.48%
on 06/25/25
157.29 -21.32%
on 02/11/26
+15.76 (+14.59%)
since 06/18/25

Most Recent Stories

More News
Gilead Sciences (GILD): Buy, Sell, or Hold Post Q1 Earnings?

Gilead Sciences (GILD): Buy, Sell, or Hold Post Q1 Earnings?

GILD : 123.76 (-1.35%)
1 Cash-Producing Stock Worth Investigating and 2 We Brush Off

1 Cash-Producing Stock Worth Investigating and 2 We Brush Off

SEDG : 58.05 (+6.16%)
HRB : 34.38 (-2.66%)
GILD : 123.76 (-1.35%)
U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention

– Submission Supported By Clinical Profile of Lenacapavir, Which Demonstrated High Efficacy in HIV Prevention Across Two Clinical Trials –

GILD : 123.76 (-1.35%)
Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief

Gilead Sciences today announced a donation of more than 2,000 vials of its intravenous antiviral therapy, remdesivir, to the Republic of Uganda to support response efforts to the current outbreak of Ebola...

GILD : 123.76 (-1.35%)
National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership

- Three-year, ~$3M commitment to expand leadership development, strengthen HIV education and engagement, and preserve the HIV movement’s history for future generations -

GILD : 123.76 (-1.35%)
Stocks Climb on an AI-Led Rebound

The S&P 500 Index ($SPX ) (SPY ) today is up +0.93%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.89%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.17%. June E-mini S&P futures (ESM26...

ALK : 49.26 (+2.05%)
MPC : 242.91 (-0.69%)
SNDK : 2,184.75 (+11.54%)
MTN : 144.78 (+11.43%)
OXY : 51.82 (-2.30%)
FANG : 183.50 (-1.07%)
STX : 1,070.23 (+0.39%)
WDC : 746.23 (+4.79%)
NUVL : 123.43 (+0.06%)
NOVT : 155.30 (+2.56%)
SPY : 746.74 (+1.04%)
MU : 1,133.99 (+8.70%)
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment

– Novel Investigational Combination Pairs Merck’s Islatravir, a Next-Generation Nucleoside Analog with Distinct Mechanisms of Action, Including Reverse Transcriptase Translocation Inhibition, with...

MRK : 113.87 (-1.36%)
GILD : 123.76 (-1.35%)
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Gilead Sciences, Inc. (Nasdaq: GILD) today announced the discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 study investigating...

MRK : 113.87 (-1.36%)
GILD : 123.76 (-1.35%)
Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa

Gilead applauds the leadership of the Government of South Africa and the Global Fund for accelerating access to lenacapavir, a long-acting HIV prevention medication. This marks an important step toward...

GILD : 123.76 (-1.35%)
Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline

– Companies will collaborate on the development of gamgertamig, a potential first-in-class and best-in-class T cell engager in autoimmune diseases –

GILD : 123.76 (-1.35%)
LKFT : 28.30 (-0.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya,...

See More

Key Turning Points

3rd Resistance Point 129.92
2nd Resistance Point 128.15
1st Resistance Point 125.96
Last Price 123.76
1st Support Level 122.00
2nd Support Level 120.23
3rd Support Level 118.04

See More

52-Week High 157.29
Fibonacci 61.8% 137.11
Fibonacci 50% 130.88
Fibonacci 38.2% 124.64
Last Price 123.76
52-Week Low 104.46

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.